Format

Send to

Choose Destination
Sex Health. 2010 Sep;7(3):320-4. doi: 10.1071/SH09153.

Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance.

Author information

1
Discipline of Paediatrics, School of Paediatrics and Reproductive Health, University of Adelaide, SA 5001, Australia. michael.gold@adelaide.edu.au

Abstract

Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8 million doses of Gardasil((R)) (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conversion disorders and lipoatrophy) and otherwise (multiple sclerosis and pancreatitis) have been published.

PMID:
20719221
DOI:
10.1071/SH09153
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for CSIRO
Loading ...
Support Center